Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Kosuke Takemura,Audreylie Lemelin,Matthew S Ernst,J Connor Wells,Renee Maria Saliby,Talal El Zarif,Chris Labaki,Naveen S Basappa,Bernadett Szabados,Thomas Powles,Ian D Davis,Lori A Wood,Aly-Khan A Lalani,Rana R McKay,Jae-Lyun Lee,Luis Meza,Sumanta K Pal,Frede Donskov,Takeshi Yuasa,Benoit Beuselinck,Georges Gebrael,Neeraj Agarwal,Toni K Choueiri,Daniel Y C Heng,Matthew S. Ernst,J. Connor Wells,Naveen S. Basappa,Ian D. Davis,Lori A. Wood,Aly-Khan A. Lalani,Rana R. McKay,Sumanta K. Pal,Toni K. Choueiri,Daniel Y.C. Heng
DOI: https://doi.org/10.1016/j.eururo.2024.01.006
IF: 24.267
2024-01-01
European Urology
Abstract:Patients with brain metastases (BrM) from renal cell carcinoma and their outcomes are not well characterized owing to frequent exclusion of this population from clinical trials. We analyzed data for patients with or without BrM using the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). A total of 389/4799 patients (8.1%) had BrM on initiation of systemic therapy. First-line immuno-oncology (IO)-based combination therapy was associated with longer median overall survival (OS; 32.7 mo, 95% confidence interval [CI] 22.3-not reached) versus tyrosine kinase inhibitor monotherapy (20.6 mo, 95% CI 15.7-24.5; p = 0.019), as were intensive focal therapies with stereotactic radiotherapy or neurosurgery (31.4 mo, 95% CI 22.3-37.5) versus whole-brain radiotherapy alone or no focal therapy (16.5 mo, 95% CI 10.2-21.1; p = 0.028). On multivariable analysis, IO-based regimens (HR 0.49, 95% CI 0.25-0.97; p = 0.040) and stereotactic radiotherapy or neurosurgery (HR 0.48, 95% CI 0.29-0.78; p = 0.003) were independently associated with longer OS, as was IMDC favorable or intermediate risk (HR 0.40, 95% CI 0.24-0.66; p < 0.001). Intensive systemic and focal therapies were associated with better prognosis in this population. Further studies should explore the clinical effectiveness of multimodal strategies. PATIENT SUMMARY: In a large group of patients with advanced kidney cancer, we found that 8.1% had brain metastases when starting systemic therapy. Patients with brain metastases had significantly poorer prognosis than those without brain metastases. Receipt of combination immunotherapy, stereotactic radiotherapy, or neurosurgery was associated with longer overall survival.
urology & nephrology